Overview

• The Hospital Universitari de Bellvitge and spin‑off ADmit Therapeutics report MAP‑AD as a prognostic blood biomarker for people with mild cognitive impairment who will progress to Alzheimer’s disease.
• Peer‑reviewed data in iScience show about 84% accuracy in studied blood samples from patients who later developed Alzheimer’s dementia.
• The test has obtained CE‑IVDR certification, clearing it for clinical use in the European Union, with Bellvitge coordinating clinical work and IDIBELL as the originating research center.
• Unlike amyloid or tau assays, MAP‑AD measures mitochondrial DNA methylation patterns, with analysis aided by artificial intelligence to detect predictive changes.
• Researchers highlight potential uses in earlier counseling, trial recruitment and treatment planning, while noting the need for broader validation and health‑system guidance as Europe’s disease‑modifying antibodies roll out unevenly.